LakeShore Biopharma Shares Higher on Unchanged FY Guidance

Dow Jones10-09

By Sabela Ojea

Shares of LakeShore Biopharma climbed after the company kept its outlook for fiscal 2025 unchanged following a 28% to 39% increase in revenue in the first half of the year.

The stock was up 7.9% to $3.57 on Tuesday. Shares have, however, plunged 48% on a month-to-date basis.

The developer and manufacturer of vaccines and other immune products said its performance during the first six months of the fiscal year ending March 31, 2025, demonstrated solid progress toward its full-year goals.

For fiscal 2025, the company most recently guided for double-digit year-over-year revenue growth, and said it expected to achieve breakeven during the period.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

October 08, 2024 13:58 ET (17:58 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474640135?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-09 01:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474640135","market":"fut","top_or_hot":-1,"title":"LakeShore Biopharma Shares Higher on Unchanged FY Guidance","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of LakeShore Biopharma climbed after the company kept its outlook for fiscal 2025 unchanged following a 28% to 39% increase in revenue in the first half of the year. \n</p>\n<p>\n  The stock was up 7.9% to $3.57 on Tuesday. Shares have, however, plunged 48% on a month-to-date basis. \n</p>\n<p>\n  The developer and manufacturer of vaccines and other immune products said its performance during the first six months of the fiscal year ending March 31, 2025, demonstrated solid progress toward its full-year goals. \n</p>\n<p>\n  For fiscal 2025, the company most recently guided for double-digit year-over-year revenue growth, and said it expected to achieve breakeven during the period. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 08, 2024 13:58 ET (17:58 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LakeShore Biopharma Shares Higher on Unchanged FY Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLakeShore Biopharma Shares Higher on Unchanged FY Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-09 01:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sabela Ojea \n\n\n \n\n\n  Shares of LakeShore Biopharma climbed after the company kept its outlook for fiscal 2025 unchanged following a 28% to 39% increase in revenue in the first half of the year. \n\n\n...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LSB","symbol_name":"LakeShore Biopharma Co., Ltd.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2474640135","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474640135","pubTimestamp":1728410280,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of LakeShore Biopharma climbed after the company kept its outlook for fiscal 2025 unchanged following a 28% to 39% increase in revenue in the first half of the year.The stock was up 7.9% to $3.57 on Tuesday. Shares have, however, plunged 48% on a month-to-date basis.The developer and manufacturer of vaccines and other immune products said its performance during the first six months of the fiscal year ending March 31, 2025, demonstrated solid progress toward its full-year goals.For fiscal 2025, the company most recently guided for double-digit year-over-year revenue growth, and said it expected to achieve breakeven during the period.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LSB":"LakeShore Biopharma Co., Ltd.","BK4139":"生物科技"},"translate_title":"LakeShore Biopharma股价因财年指引不变而走高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LSB":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of LakeShore Biopharma climbed after the company kept its outlook for fiscal 2025 unchanged following a 28% to 39% increase in revenue in the first half of the year. \n\n\n  The stock was up 7.9% to $3.57 on Tuesday. Shares have, however, plunged 48% on a month-to-date basis. \n\n\n  The developer and manufacturer of vaccines and other immune products said its performance during the first six months of the fiscal year ending March 31, 2025, demonstrated solid progress toward its full-year goals. \n\n\n  For fiscal 2025, the company most recently guided for double-digit year-over-year revenue growth, and said it expected to achieve breakeven during the period. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 08, 2024 13:58 ET (17:58 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474640135"}